Odyssey Therapeutics, Inc.
NASDAQ:ODTXBiotechnology
-$0.01 today
- Market cap
- $912.33M
- Beta
- 0.00
Volume 0.37M
Average 0.43M
ODTX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
EBITDA history
Currency unavailable · from the income statement
No EBITDA data reported for this period type.
EBITDA vs competitors
How ODTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $85.88M USD | +54.7% | — | 30.5% | |
| LTM Mar 2026 | $58.49M USD | +176.6% | — | 25.2% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | -€45.89M EUR | -286.3% | — | — |
| LTM Mar 2026 | -$70.61M USD | -31.5% | — | 843.9% | |
| LTM Mar 2026 | -$104.13M USD | -8.2% | — | — | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | -$161.31M USD | -42.5% | — | — |
| LTM Sep 2026 | -$280.09M USD | -70.6% | — | 309.5% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -$442.87M USD | -9.5% | — | 5986.3% |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ODTX) | — | -20.5% | — | 309.5% | |
Competitors are the stored peer set for ODTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Odyssey Therapeutics, Inc.
NASDAQ:ODTX
Intrinsic Alpha fair value
Locked
Current Price
$18.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.